ClinicalTrials.gg
Not yet recruitingNCT06974669NCESUpdated May 16, 2025

The Value of Using Mini-oral Pulse Steroid Therapy Along With Non Cultured Epidermal Cell Suspension (NCES) in Stable Resistant Vitiligo

An interventional study of oral steroid-dexamethasone and non cultured epidermal suspension in Vitiligo, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Vitiligo by Cairo University — 7 open to participants now, 7 under way, 1 of them phase 3. Vitiligo · Cairo University.

Planned enrollment
5th of 18
40 · median 30
Started
2025
with 3 others
No phase
11 of 24
2 open now
Registered
17th of 24
by date

Among the 24 studies in Vitiligo by Cairo University, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, and was the 17th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

7 of the 24 studies in Vitiligo by Cairo University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Vitiligo by Cairo University, or all of them as a file.
02

Study summary

Assessing the additive value of mini-oral pulse steroid therapy in surgical treatment of acral and difficult to treat sites of vitiligo

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • vitiligo
  • surgery
  • mini-oral pulse steroid therapy
  • resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with non-segmental vitiligo (NSV) with acral or resistant lesions over the elbows and knees, that has not responded to conventional treatment
  • Stability for ≥ 1 year
  • Age ≥18 years
  • Lack of topical treatment for at least 1 month prior to surgery and systemic treatment for at least 3 months prior to surgery.

Exclusion criteria

Exclusion Criteria:

  • Non acral NSV responsive to conventional treatment modalities
  • Active vitiligo; new lesions, expansion of old lesions, confetti like lesions, ill-defined edges or koebnerization in \< 1 year
  • Age \< 18 years.
  • Pregnant females.
  • Patients with hypertension, diabetes or tuberculosis
  • Topical treatment in the past month and systemic treatment in the past 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Vitiligo surgery with added mini-oral pulse steroid therapy in the peri-surgical period

    this group will receive oral mini-pulse steroids (low-dose dexamethasone: 5mg/week on 2 successive days per week) for 2 weeks prior to NCES and for 4 weeks afterwards

    Drug: oral steroid-dexamethasone · Procedure: non cultured epidermal suspension

  • Active comparator
    Vitiligo surgery without mini-oral pulse steroid therapy

    this group will undergo None cultured epidermal suspension (NCES) without oral mini-pulse steroids.

    Procedure: non cultured epidermal suspension

Interventions

  • Drugoral steroid-dexamethasone

    this study is the first according to the best of our knowledge assessing the value of adding mini oral pulse steroid therapy to non cultured epidermal suspension in treatment of stable acral and difficult to treat vitiligo

  • Procedurenon cultured epidermal suspension

    this is the best surgical technique for surgical treatment of vitiligo that would be done for both arms

06

What researchers measure

Primary outcomes

  1. comparing percent change in pigmentation in both arms

    • Comparing percent change of pigmentation as per VESTA score after 3 months of treatment with NCES with and without mini oral pulse steroids.

    Time frame: 3 months

  2. comparing percent change in surface area in both arms

    • Comparing percent change in the surface area of the depigmented patch following NCES using point counting technique.

    Time frame: 3 months

Secondary outcomes

  1. comparing physician global assessment in both arms

    • Comparing physician global assessment after treatment with NCES with and without oral mini-pulse therapy

    Time frame: 3 months

07

Study locations

1 site
  • Dermatology Department, Cairo University Hospitals
    Giza, 12655, Egypt
    • Rania Mogawer · Contact106816339
08

References and documents

Individual participant data

Plan to share: Yes — Participants' data that underlie reported results will be shared upon request, after deidentification

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: within 3 months and for 12 months after completion of the study

Access criteria: Controlled Access: Researchers who provide a methodologically sound proposal will be allowed to access data to achieve aims in the approved proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Aug 2025, 3 months later.

Of 63 non-industry interventional studies with no phase under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 3 months is below that.

Counting every sponsor, half of 67 studies reached it within 17 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartEst.
May 12, 2025
Primary completionEst.
Aug 15, 2025
CompletionEst.
Oct 1, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974669
Lead sponsor
Cairo University
Responsible party
Rania Mogawer (Lecturer of Dermatology, Cairo University) — Principal investigator
First posted
May 16, 2025
Start date
May 12, 2025 (estimated)
Primary completion
Aug 15, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
May 16, 2025

Study contacts

Dr. Mogawer, MD, PhD
Contact
raniamogawer@kasralainy.edu.eg
+20106815330
Prof. Nanis Ragab, MD, PhD
Contact
nanisragab@kasralainy.edu.eg
+201227449161
Dr. Mogawer, MD, PhD
principal investigator · Dermatology Department, Cairo University Hopsitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion